Source comparison
Tesamorelin Ipamorelin: Stack Comparison
Research teams often compare tesamorelin ipamorelin to other peptide combinations or single-agent GH secretagogues. The comparison hinges on mechanism specificity, side effect profile, and downstream IGF-1 output. Tesamorelin Ipamorelin GHRH amplification + se
This comparison does not assign a generated winner or score.
- Research teams often compare tesamorelin ipamorelin to other peptide combinations or single-agent GH secretagogues. The comparison hinges on mechanism specificity, side effect profile, and downstream IGF-1 output.
- Tesamorelin Ipamorelin
- GHRH amplification + selective ghrelin agonism
- 60–90 min
- None (ipamorelin is selective)
- +70–100 ng/mL at 12 weeks
- Cleanest synergistic stack—minimal endocrine side effects, additive GH pulse amplitude
- CJC-1295 Ipamorelin
- Long-acting GHRH analog + ghrelin agonism
- 90–180 min (CJC half-life ~6–8 days)
- None
- +80–120 ng/mL at 12 weeks
- Higher sustained IGF-1 due to CJC's extended half-life, but less pulsatile—more continuous GH elevation
- Sermorelin Ipamorelin
- Short-acting GHRH analog + ghrelin agonism
- 30–60 min
- +50–70 ng/mL at 12 weeks
- Lower IGF-1 output—sermorelin's half-life (~10 min) limits GHRH receptor occupancy time
- GHRP-2 + GHRH
- Non-selective ghrelin agonism + GHRH
- 45–75 min
- Moderate (GHRP-2 elevates cortisol ~30–50%)
- +60–90 ng/mL at 12 weeks
- Effective GH synergy but cortisol spike complicates metabolic interpretation—less clean for research
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic, long half-life (~24 hr)
- Continuous elevation
- Moderate (some prolactin increase reported)
- +60–80 ng/mL at 12 weeks
- Convenient oral dosing but sustained receptor occupancy risks desensitization—not pulsatile
- Tesamorelin Alone
- GHRH amplification only
- FDA-approved for lipodystrophy; strong monotherapy but lacks ghrelin pathway synergy
- Tesamorelin ipamorelin offers the best balance of receptor specificity, pulsatile GH release, and freedom from cortisol or prolactin side effects. The synergy is real—measured by higher peak GH and faster IGF-1 elevation than either peptide alone—but the effect is bounded by natural somatostatin cycles, so it cannot override inhibitory signaling the way exogenous GH would.